Bristi Basu

Generating author description...

All published works

Action	Title	Year	Authors
+ PDF Chat	Early Phase Clinical Trial Designs – State of Play and Adapting for the Future	2017	Jennifer Harrington T.C. Hernandez-Guerrero Bristi Basu
+	Creatinine Clearance Is Associated with Toxicity from Molecularly Targeted Agents in Phase I Trials	2012	Bristi Basu J. Vitfell-Pedersen Víctor Moreno M. Puglisi Angelina Tjokrowidjaja Krunal Shah S. Malvankar B. Anghan Johann S. de Bono Stan B. Kaye

Common Coauthors

Coauthor	Papers Together
Víctor Moreno	1
B. Anghan	1
Stan B. Kaye	1
Krunal Shah	1
Udai Banerji	1
S. Malvankar	1
Jennifer Harrington	1
J. Vitfell-Pedersen	1
T.C. Hernandez-Guerrero	1
Angelina Tjokrowidjaja	1
M. Puglisi	1
Johann S. de Bono	1
L Rhoda Molife	1

Commonly Cited References

Action	Title	Year	Authors	# of times referenced
+ PDF Chat	Dose Escalation Methods in Phase I Cancer Clinical Trials	2009	Christophe Le Tourneau J. Jack Lee Lillian L. Siu	2
+	Phase I Trials of Molecularly Targeted Agents: Should We Pay More Attention to Late Toxicities?	2011	Sophie Postel‐Vinay Carlos Gomez‐Roca L Rhoda Molife B. Anghan Antonin Lévy Ian Judson Johann S. de Bono Jean‐Charles Soria Stan B. Kaye Xavier Paolettí	2
+ PDF Chat	Risks and Benefits of Phase 1 Oncology Trials, 1991 through 2002	2005	Elizabeth Horstmann Mary S. McCabe Louise B. Grochow Seiichiro Yamamoto Larry Rubinstein Troy Budd Dale Shoemaker Ezekiel Emanuel Christine Grady	2
+ PDF Chat	Modified Toxicity Probability Interval Design: A Safer and More Reliable Method Than the 3 + 3 Design for Practical Phase I Trials	2013	Yuan Ji Sue-Jane Wang	1
+ PDF Chat	Model‐based phase I designs incorporating toxicity and efficacy for single and dual agent drug combinations: Methods and challenges	2010	Sumithra J. Mandrekar Rui Qin Daniel J. Sargent	1
+ PDF Chat	Early phase clinical trials to identify optimal dosing and safety	2014	Natalie Cook Aaron R. Hansen Lillian L. Siu Albiruni R. Abdul Razak	1
+ PDF Chat	Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?	2009	Sophie Postel‐Vinay H-T Arkenau David Olmos Joo Ern Ang Jorge Barriuso Sue Ashley Udai Banerji Johann S. de Bono Ian Judson S.B. Kaye	1
+	A pragmatic dose‐finding approach using short‐term surrogate efficacy outcomes to evaluate binary efficacy and toxicity outcomes in phase I cancer clinical trials	2013	T. Asakawa Chikuma Hamada	1
+	Continual reassessment methods in phase I trials of the combination of two drugs in oncology	1999	Andrew Kramar Anne Lebecq Emmanuel Candalh	1
+	Adaptive designs for dual-agent phase I dose-escalation studies	2013	Jennifer Harrington Graham Wheeler Michael Sweeting Adrian Mander Duncan I. Jodrell	1
+	Practical modifications of the continual reassessment method for phase i cancer clinical trials	1994	Douglas E. Faries	1
+	Heterogeneity in phase I clinical trials: prior elicitation and computation using the continual reassessment method	2001	Anna Legedza Joseph G. Ibrahim	1
+ PDF Chat	Design of Phase I Combination Trials: Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee	2014	Channing J. Paller Penelope A. Bradbury S. Percy Ivy Lesley Seymour Patricia LoRusso Laurence H. Baker Larry Rubinstein Erich Huang Deborah Collyar Susan Groshen	1
+ PDF Chat	Escalation strategies for combination therapy Phase I trials	2012	Michael Sweeting Adrian Mander	1
+	Adaptive clinical trials in oncology	2011	Donald A. Berry	1
+ PDF Chat	Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents	2003	Chengcheng Han Jeremy Braybrooke G. Deplanque M Taylor David Mackintosh Kanchan Kaur K Samouri Trivadi S. Ganesan Adrian L. Harris Denis Talbot	1
+ PDF Chat	Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials	2014	Zhengjia Chen Ye Cui Taofeek K. Owonikoko Zhibo Wang Zheng Li Ruiyan Luo Michael Kutner Fadlo R. Khuri Jeanne Kowalski	1
+	Adaptive designs for selecting drug combinations based on efficacy–toxicity response	2007	Vladimir Dragalin Valerii V. Fedorov Yuehui Wu	1
+ PDF Chat	Utility‐Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials	2009	Nadine Houedé Peter F. Thall Hoang Q. Nguyen Xavier Paolettí Andrew Kramar	1
+	A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents	2008	Guosheng Yin Ying Yuan	1
+	Dose‐finding design using mixed‐effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trials	2013	A. Doussau Rodolphe Thiébaut Xavier Paolettí	1
+	Design and Analysis of Phase I Clinical Trials	1989	Barry E. Storer	1
+ PDF Chat	Up-and-down designs for phase I clinical trials	2013	Suyu Liu Chunyan Cai Jing Ning	1
+	A two-stage algorithm for designing phase I cancer clinical trials for two new molecular entities	2009	Zheng Su	1
+	The no-observed-adverse-effect-level in drug safety evaluations: Use, issues, and definition(s)	2005	Michael A. Dorato Jeffery A. Engelhardt	1
+	Fractional Dose-Finding Methods with Late-Onset Toxicity in Phase I Clinical Trials	2013	Guosheng Yin Shurong Zheng Jiajing Xu	1
+	Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer	1990	John O’Quigley Margaret S. Pepe Lloyd D. Fisher	1
+	Determining the optimal dose in the development of anticancer agents	2014	Ron H.J. Mathijssen Alex Sparreboom Jaap Verweij	1
+	An adaptive dose-finding design incorporating both toxicity and efficacy	2005	Wei Zhang Daniel J. Sargent Sumithra J. Mandrekar	1
+	Two‐Dimensional Dose Finding in Discrete Dose Space	2005	Kai Wang Anastasia Ivanova	1
+ PDF Chat	Incorporating adverse event relatedness into dose‐finding clinical trial designs	2013	Darsy Darssan Helen Thompson A. N. Pettitt	1
+ PDF Chat	Nomograms to Predict Serious Adverse Events in Phase II Clinical Trials of Molecularly Targeted Agents	2008	Gregory R. Pond Lillian L. Siu Malcolm J. Moore Amit M. Oza Hal W. Hirte Eric Winquist Glenwood D. Goss Gary R. Hudes Carol Townsley	1
+	IMPROVED DESIGNS FOR DOSE ESCALATION STUDIES USING PHARMACOKINETIC MEASUREMENTS	1996	Steven Piantadosi G. Frank Liu	1
+ PDF Chat	Bayesian Approaches to Clinical Trials and Health-Care Evaluation	2004	Mark A. Best	1
+ PDF Chat	A Bayesian adaptive Phase I–II clinical trial for evaluating efficacy and toxicity with delayed outcomes	2013	Joseph S. Koopmeiners Jaime F. Modiano	1
+ PDF Chat	American Society of Clinical Oncology Policy Statement Update: The Critical Role of Phase I Trials in Cancer Research and Treatment	2014	Jeffrey S. Weber Laura A. Levit Peter C. Adamson Suanna S. Bruinooge Howard A. Burris Michael A. Carducci Adam P. Dicker Mithat Gönen Stephen J. O’Keefe Michael A. Postow	1
+ PDF Chat	Dose finding with drug combinations in cancer phase I clinical trials using conditional escalation with overdose control	2014	Mourad Tighiouart Steven Piantadosi André Rogatko	1
+ PDF Chat	Phase I Trial Design for Solid Tumor Studies of Targeted, Non-Cytotoxic Agents: Theory and Practice	2004	Wendy R. Parulekar Elizabeth A. Eisenhauer	1
+ PDF Chat	Workshop on phase I study design	1996	Susan G. Arbuck	1
+ PDF Chat	Accelerated Titration Designs for Phase I Clinical Trials in Oncology	1997	Richard Simon Larry Rubinstein Susan G. Arbuck Michaele C. Christian Boris Freidlin Jerry M. Collins	1
+ PDF Chat	Early phase trial design for assessing several dose levels for toxicity and efficacy for targeted agents	2013	Antje Hoering Alan Mitchell Michael LeBlanc John Crowley	1
+	90-Days mortality rate in patients treated within the context of a phase-I trial: How should we identify patients who should not go on trial?	2008	Hendrik‐Tobias Arkenau David Olmos Joo Ern Ang Jorge Barriuso Vasilios Karavasilis S. Ashley Johann S. de Bono Ian Judson Stan B. Kaye	1
+	A Bayesian approach to dose-finding studies for cancer therapies: incorporating later cycles of therapy	2014	Karen Sinclair Anne Whitehead	1
+	Phase I Trial Improvement: A Question of Patient Selection, Trial Design, or Both?	2014	Karla V. Ballman	1
+	Trends in the Risks and Benefits to Patients With Cancer Participating in Phase 1 Clinical Trials	2004	Thomas G. Roberts	1
+	Model-Guided Determination of Maximum Tolerated Dose in Phase I Clinical Trials: Evidence for Increased Precision	1993	Rosemarie Mick MJ Ratain	1
+ PDF Chat	Translation of Innovative Designs Into Phase I Trials	2007	André Rogatko David J. Schoeneck William Jonas Mourad Tighiouart Fadlo R. Khuri Alan L. Porter	1
+ PDF Chat	Toxicity burden score: a novel approach to summarize multiple toxic effects	2011	S. M. Lee Dawn L. Hershman Peter Martin John P. Leonard Ying Kuen Cheung	1
+	Some practical improvements in the continual reassessment method for phase I studies	1995	Steven N. Goodman Marianna Zahurak Steven Piantadosi	1
+	What Is the Right Dose? The Elusive Optimal Biologic Dose in Phase I Clinical Trials	2006	Alex A. Adjei	1